These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 30224228)

  • 1. What's new in the treatment of multidrug-resistant gram-negative infections?
    Mo Y; Lorenzo M; Farghaly S; Kaur K; Housman ST
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):171-181. PubMed ID: 30224228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
    Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
    Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections.
    Jabbour JF; Sharara SL; Kanj SS
    Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria.
    Giacobbe DR; Mikulska M; Viscoli C
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1219-1236. PubMed ID: 30444147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
    Sherry N; Howden B
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
    Rodriguez BA; Girotto JE; Nicolau DP
    Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
    Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
    [No Abstract]   [Full Text] [Related]  

  • 13. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Avery LM; Nicolau DP
    Expert Opin Investig Drugs; 2018 Apr; 27(4):325-338. PubMed ID: 29611447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Tamma PD; Hsu AJ
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistant gram-negative bacteria. Therapeutic approach and risk factors].
    Salgado P; Gilsanz F; Maseda E
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():26-30. PubMed ID: 27608309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.
    Hawkey PM; Warren RE; Livermore DM; McNulty CAM; Enoch DA; Otter JA; Wilson APR
    J Antimicrob Chemother; 2018 Mar; 73(suppl_3):iii2-iii78. PubMed ID: 29514274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.